Skip to main content
OpenTrials
Completed

NCT Number: NCT02221141

Screening of Fabry Disease in Patients With Left Ventricular Hypertrophy Detected in Echocardiography

The purpose of this study is to determine the prevalence in Belgium of Fabry disease in patients with unexplained hypertrophic cardiomyopathy measured by echocardiography and to determine in Fabry patients which was the most frequently initial symptom.

Actually the early diagnosis is important because a treatment exists that can prevent future complications.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Dinant-Godinne

Yvoir, 5530, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • unexplained left ventricular hypertrophy

Exclusion criteria

  • isolated septal hypertrophy

Treatment and study plan

Primary outcomes

  1. Percentage of patients with left ventricular hypertrophy who have Fabry Disease mutation

    Time frame: 1 day

Sponsors and collaborators

Lead sponsor

Laurence Gabriel

Other

Registry information

Important dates

Study start
2013
Primary completion
2021
Study completion
2021
First posted
Aug 20, 2014
Registry last updated
Aug 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.